International Journal of Pharmaceutics and Drug Research
ISSN: 2347-6346
Available online at http://ijpdr.com

Review Article

REVIEW ON CONTROLLED DRUG DELIVERY SYSTEMS

Md. Anas Mansoori*, Chandra Chaurasia, B. K. Dubey

Technocrats Institute of Technology-Pharmacy, Bhopal (M.P.)

***Correspondence Info:**
Md. Anas Mansoori
Technocrats Institute of Technology-Pharmacy, Bhopal (M.P.)
Email: anasmansoori@gmail.com

***Article History:**

Received: 11/10/2024
Revised: 26/10/2024
Accepted: 20/11/2024

ABSTRACT

Controlled drug delivery systems (CDDS) represent a significant advancement in the field of pharmacology, offering sustained and targeted delivery of therapeutic agents to improve the effectiveness and safety of treatment. These systems are designed to release drugs at a predetermined rate, maintaining therapeutic drug concentrations for extended periods and minimizing side effects. CDDS can be classified into various types, including oral, transdermal, injectable, and implantable systems, each designed to meet specific clinical requirements. The mechanisms behind CDDS, such as diffusion, erosion, and swelling, play crucial roles in determining the release profiles of drugs. Furthermore, the materials used for constructing CDDS, including polymers, lipids, and nanoparticles, have seen significant evolution to enhance biocompatibility, stability, and controlled release properties. This review article discusses the different types of controlled drug delivery systems, their mechanisms, and their applications in the treatment of chronic diseases, cancer therapy, and personalized medicine. The challenges in designing efficient CDDS, such as patient compliance, stability, and regulatory hurdles, are also addressed. Finally, the future prospects of CDDS, including the integration of nanotechnology and stimuli-responsive materials, are discussed as promising strategies for improving drug delivery systems.

Keywords: Controlled drug delivery systems, sustained release, targeted therapy, drug release mechanisms, polymers, lipids, nanoparticles, chronic diseases, cancer therapy, personalized medicine, nanotechnology, stimuli-responsive materials.

INTRODUCTION

Controlled drug delivery systems (CDDS) are designed to administer drugs at a specific rate, duration, and location within the body to achieve optimal therapeutic outcomes. Unlike conventional drug delivery methods, which involve the rapid release of a drug into the bloodstream, CDDS aim to provide a sustained and controlled release of medication, thereby enhancing patient compliance, reducing side effects, and improving drug efficacy. CDDS have gained significant attention in recent decades due to their potential to revolutionize the way drugs are administered, particularly for chronic diseases and conditions requiring long-term therapy (Jain & Jain, 2009; Dash & Konkimalla, 2012).

The basic principle behind CDDS is to maintain a consistent drug concentration at the target site for an extended period, minimizing fluctuations in drug levels and ensuring that the therapeutic effect is sustained over time.

Various techniques have been developed to achieve controlled release, including the use of polymers, liposomes, microemulsions, and nanoparticles (Patel & Patel, 2013).

Types of Controlled Drug Delivery Systems (CDDS)

Controlled Drug Delivery Systems (CDDS) are designed to release a drug at a controlled rate, enhancing the therapeutic efficacy and minimizing side effects. These systems are tailored to maintain a specific drug concentration in the bloodstream for an extended period, reducing the need for frequent dosing. There are several types of CDDS, each suited for different applications depending on the disease condition, drug characteristics, and desired release profiles. Below are the main types of CDDS, elaborated with examples and references.

Oral Controlled Drug Delivery Systems

Oral drug delivery remains the most commonly used method for controlled drug release, as it is non-invasive, convenient, and generally well-accepted by patients. The primary goal of oral controlled delivery systems is to release the drug at a steady rate, reducing fluctuations in drug concentrations and minimizing side effects.

Matrix Tablets

Matrix tablets are one of the most widely used oral controlled drug delivery systems. These tablets consist of a drug dispersed within a polymer matrix. The drug is released via diffusion through the polymer network or by the erosion of the matrix itself.

Hydrophilic matrix tablets containing drugs like metformin and propranolol. These tablets release the drug in a controlled manner over hours as water penetrates the matrix, causing the polymer to swell and release the drug gradually (Sharma & Singh, 2015).

Coated Tablets

Coated tablets are another common oral controlled drug delivery system. In this system, the drug is contained within a tablet core and coated with a polymeric material. The coating can be designed to dissolve under specific conditions, such as in response to pH changes in the gastrointestinal tract, thereby controlling the release rate. Enteric-coated tablets, such as those for ibuprofen, are designed to resist stomach acid and dissolve in the intestines, ensuring that the drug is released in a controlled manner once it reaches the desired site (Jain & Jain, 2009).

c. Osmotic Pump Systems

Osmotic pump systems use the principle of osmosis to control drug release. These systems consist of a core containing the drug and an osmotic agent surrounded by a semipermeable membrane. When the tablet is ingested, water enters the system, creating osmotic pressure that pushes the drug out at a controlled rate. The Oros® system is used for drugs like hydromorphone and theophylline, where the drug is released over a prolonged period through an osmotic mechanism (Patel & Patel, 2013).

Injectable Controlled Drug Delivery Systems

Injectable systems are used for delivering drugs directly into the bloodstream or at a specific site of action. These systems are useful for treating conditions that require fast, localized, or prolonged drug release.

Hydrogels

Hydrogels are water-swelling polymers that can absorb significant amounts of water and release drugs in a controlled manner.

These systems can be injected as a liquid, where they then form a gel upon contact with body fluids, slowly releasing the encapsulated drug. Hydrogels for insulin delivery in diabetic patients. These hydrogels release insulin in a sustained manner over a long period, reducing the need for multiple injections (Dash & Konkimalla, 2012).

Microspheres and Nanoparticles

Microspheres and nanoparticles are solid particulate systems that can be loaded with drugs. These systems can be injected into the body, where they slowly release the drug through mechanisms such as diffusion, degradation, or erosion. Polymeric microspheres containing antiretroviral drugs used in HIV therapy. The microspheres are injected subcutaneously and release the drug in a sustained fashion over several weeks (Bhalekar & Momin, 2015).

Implants

Implants are small devices or systems that are placed under the skin to release drugs over an extended period. These systems are particularly beneficial for chronic conditions that require long-term treatment, such as hormone replacement therapy or cancer treatment. The Norplant® implant is used for contraceptive purposes and releases a progestin hormone over a period of several years (Sharma & Singh, 2015).

Transdermal Controlled Drug Delivery Systems

Transdermal systems involve the application of a drug through the skin. These systems are designed to release drugs at a controlled rate over an extended period, providing a non-invasive method for drug administration.

Transdermal Patches

Transdermal patches are designed to release the drug slowly through the skin, ensuring continuous and controlled delivery to the bloodstream. The patch is typically applied to the skin for a set duration, and it delivers the drug in a controlled manner through the skin's layers. The fentanyl patch, used for pain management, delivers the drug continuously over 72 hours, providing consistent analgesic effects (Patel & Patel, 2013).

Microneedle Patches

Microneedle patches contain tiny needles that create microscopic holes in the skin, allowing for drug delivery directly into the dermal layer. These systems can be used for the delivery of both small molecules and macromolecules like proteins or vaccines. Microneedle patches for the delivery of insulin in diabetic patients, allowing for non-invasive, controlled drug delivery (Jain & Jain, 2009).

Topical Controlled Drug Delivery Systems

Topical drug delivery systems are designed to apply the drug directly to the skin or mucosal membranes, allowing for localized treatment. These systems are particularly useful in dermatological treatments, providing sustained release of active ingredients.

Topical Gels

Topical gels are commonly used for controlled release of drugs applied to the skin. These gels typically contain a drug suspended in a polymeric base, allowing for the sustained release of the drug over time. Diclofenac gel for pain management, which is applied topically to deliver the drug directly to the site of inflammation and release it over an extended period (Sharma & Singh, 2015).

Liposomes and Niosomes

Liposomes and niosomes are vesicular systems that can be used for the controlled release of drugs, including those applied topically. These systems encapsulate the drug within lipid or surfactant bilayers, which can slowly release the drug at the application site. Liposomal formulations of amphotericin B, used in the treatment of fungal infections, provide controlled release and improve skin penetration (Patel & Patel, 2013).

Pulmonary Drug Delivery Systems

Pulmonary drug delivery involves the administration of drugs to the lungs. This system is useful for local treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD), as well as for systemic drug delivery via inhalation.

Inhalers and Nebulizers

Inhalers and nebulizers are used to deliver drugs in aerosolized form directly to the lungs. These systems are designed to release drugs in a controlled manner, providing rapid onset of action for conditions like asthma and COPD. Inhalers containing bronchodilators, such as salbutamol, release the drug to relieve bronchoconstriction and provide quick relief (Dash & Konkimalla, 2012).

Stimuli-Responsive Drug Delivery Systems

Stimuli-responsive drug delivery systems release drugs in response to specific internal or external stimuli. These systems can be designed to release drugs in a controlled manner when exposed to environmental factors like pH, temperature, or light.

pH-Responsive Systems

pH-responsive systems release drugs in specific pH environments, such as the acidic stomach or the neutral pH of the intestines. These systems are especially useful in oral and targeted drug delivery applications.

pH-sensitive hydrogels that release the drug only when they reach the slightly alkaline pH of the intestines, ensuring targeted drug release (Sharma & Singh, 2015).

Temperature-Responsive Systems

Temperature-sensitive drug delivery systems release drugs in response to changes in body temperature or external temperature, which can be used for localized drug delivery. Thermoresponsive hydrogels for controlled release of insulin in diabetic patients, where the hydrogel undergoes phase transition at body temperature, releasing the drug in a controlled manner (Dash & Konkimalla, 2012).

Mechanisms of Drug Release

Drug release from pharmaceutical formulations is a crucial process that determines the therapeutic outcome of drug delivery systems (DDS). Understanding the mechanisms of drug release is essential for the development of controlled, sustained, or targeted drug delivery systems (DDS) that optimize drug effectiveness and minimize side effects. Drug release mechanisms can be broadly classified into different categories based on physical, chemical, and biological processes. Below, we explore the primary mechanisms of drug release, elaborating on their principles, examples, and references.

Diffusion-Controlled Release

Diffusion is one of the most widely studied and understood mechanisms of drug release. In this mechanism, the drug molecules move from an area of high concentration (within the drug reservoir) to an area of low concentration (outside the DDS) due to concentration

gradients. This can happen in solid, liquid, or gel systems.

Fickian Diffusion (First-Order Kinetics)

In Fickian diffusion, the rate of drug release is proportional to the concentration gradient and the diffusivity of the drug within the matrix. The release follows Fick's Law, and the rate of release depends on factors such as the drug's solubility, matrix structure, and the medium through which the drug diffuses. In matrix tablets made of hydrophilic polymers (like HPMC), the drug diffuses through the polymer matrix and is released over time.

Non-Fickian Diffusion (Anomalous Transport)

This occurs when drug release is controlled by a combination of both diffusion and polymer relaxation (swelling or erosion), leading to non-Fickian behavior. The release profile does not strictly follow Fick's law, and the rate of drug release is not constant. Drugs released from matrix tablets formed with mixtures of hydrophobic and hydrophilic polymers often exhibit non-Fickian diffusion.

Swelling-Controlled Release

Swelling-controlled release is commonly used in the formulation of hydrogels, where the drug release is driven by the swelling of the polymer matrix when exposed to aqueous environments. As the polymer absorbs water, it swells, leading to the release of the drug.

Swellable Matrices

In this system, the polymeric matrix swells upon contact with water, and the drug is released either by diffusion or by the erosion of the matrix. The rate of swelling is dependent on the water absorption capacity of the polymer.

Hydrogels like polyacrylamide or alginate-based systems, used for controlled release of proteins and peptides, where the matrix swells and allows gradual release of the drug.

pH-Sensitive Hydrogels

These hydrogels change their swelling behavior based on the pH of the environment. This allows for controlled drug release at specific sites in the body where the pH may vary (e.g., the stomach vs. the intestine). Polymers like poly(acrylic acid) or chitosan, which are used for site-specific drug delivery in the gastrointestinal tract.

Erosion-Controlled Release

In erosion-controlled release systems, the drug is incorporated into a polymeric matrix that gradually erodes over time, releasing the drug. The rate of drug release is governed by the rate of polymer degradation or erosion, which can be either bulk erosion (entire polymer erodes uniformly) or surface erosion (polymer erodes from the surface).

Surface Erosion

In surface erosion-controlled systems, the polymer erodes from the outer surface, exposing fresh drug molecules for release. This mechanism often leads to a steady and predictable drug release rate. Poly(lactic acid) (PLA) and poly(lactic-co-glycolic acid) (PLGA) microspheres used for sustained drug release in injectable formulations.

Bulk Erosion

In bulk erosion-controlled systems, the polymer degrades uniformly throughout the matrix, which allows for the release of the drug at a rate dependent on the erosion of the polymer. Polymeric drug delivery systems based on biodegradable materials like polycaprolactone (PCL) for controlled drug release in cancer therapy.

Osmotic-Controlled Release

Osmotic drug delivery is based on the principle of osmosis. The system consists of a core surrounded by a semipermeable membrane. Water enters the system, creating osmotic pressure that forces the drug out of the system at a controlled rate.

Osmotic Pump Systems

These systems are designed to release drugs at a steady rate by using osmotic pressure to drive the release process. The membrane of the osmotic pump can be designed to control the release rate based on the osmotic properties of the drug and surrounding medium. The Oros® system for drugs such as hydromorphone or theophylline, where drug release is controlled by osmotic pressure.

Mechanism of Drug Release from Nanocarriers

Nanocarriers, including liposomes, nanoparticles, and micelles, can provide sustained and controlled release of drugs by exploiting various release mechanisms such as diffusion, degradation, or triggered release.

Diffusion from Nanocarriers

In nanoparticles, the drug is encapsulated in a polymer matrix, and its release occurs via diffusion. Nanoparticles offer higher surface area and better control over the release process compared to conventional systems. Nanoparticles made from PLGA for the delivery of antiretroviral drugs, releasing the drug over an extended period.

Triggered Release from Nanocarriers

Triggered release involves the use of external stimuli (e.g., temperature, pH, magnetic fields, or light) to control the release of drugs from nanocarriers. These systems allow for precise, site-specific drug delivery. pH-sensitive nanoparticles used for the delivery of cancer drugs, where drug release is triggered in the acidic environment of a tumor.

Active Transport-Controlled Release

Active transport systems rely on biological or synthetic mechanisms that facilitate the active movement of the drug across biological barriers. These systems use energy-dependent processes to control drug release, often involving the use of carriers or transporters.

Drug Release via Active Transporters

Some drug delivery systems utilize transport proteins or nanoparticles to facilitate the active transport of drugs across biological membranes. These systems are used for the delivery of drugs that require enhanced absorption. Drug delivery systems based on cell-penetrating peptides (CPPs) that transport the drug across cellular membranes, providing controlled release.

Applications of Controlled Drug Delivery Systems (CDDS)

Controlled Drug Delivery Systems (CDDS) have transformed the way pharmaceuticals are administered, offering solutions for various therapeutic challenges. These systems are engineered to release drugs at a predetermined rate, enhancing therapeutic efficacy and reducing side effects by targeting specific tissues or releasing drugs over extended periods. CDDS are used in diverse therapeutic areas such as cancer treatment, chronic disease management, and central nervous system disorders, as well as in other specialized fields like gene therapy and vaccination.

In cancer therapy, CDDS have become vital for the controlled delivery of chemotherapeutic agents. Traditional chemotherapy often leads to systemic toxicity,

but with CDDS, drugs such as doxorubicin are encapsulated in liposomes or nanoparticles that selectively release the drug at the tumor site, thereby reducing damage to healthy tissues. The use of liposomal formulations, like Doxil®, has been particularly beneficial, showing improved accumulation in tumor cells while minimizing adverse effects (Allen & Cullis, 2013).

For chronic diseases, CDDS play a crucial role in managing conditions that require long-term medication, such as diabetes, hypertension, and cardiovascular diseases. By providing a sustained release of drugs like insulin or metoprolol, CDDS reduce the frequency of dosing, improving patient compliance. For example, insulin glargine is an extended-release formulation that helps maintain stable blood glucose levels with less frequent administration, thereby improving patient convenience and adherence (Ahmad & Akhter, 2017).

In the treatment of neurological disorders like Parkinson's disease or Alzheimer's disease, CDDS enable the controlled release of drugs to the central nervous system, where conventional treatments may fail due to short half-lives or rapid metabolism. Polymer-based systems and nanoparticles provide an effective strategy for sustained drug release, which is particularly beneficial for drugs such as dopamine agonists used in Parkinson's disease. The ability to maintain therapeutic levels of medication in the brain enhances treatment efficacy and minimizes fluctuations in drug levels (Melendez & D'Costa, 2015).

Transdermal drug delivery is another significant application of CDDS. This method allows drugs to be absorbed through the skin, bypassing the gastrointestinal tract and liver metabolism. Systems like nicotine patches for smoking cessation and estradiol patches for hormone replacement therapy are prime examples of CDDS in transdermal delivery. These formulations provide a continuous release of the active ingredient over an extended period, ensuring stable plasma concentrations without the need for frequent dosing (Prausnitz & Langer, 2008).

CDDS also find application in ophthalmic and topical drug delivery. For ocular diseases such as uveitis, controlled-release formulations, including biodegradable implants, provide localized, sustained drug delivery to the eye, reducing the need for frequent administration and minimizing systemic side effects (Binkowski & Schofield, 2015). Similarly, for dermatological conditions, topical CDDS formulations, such as gels or creams, ensure that drugs are released in a controlled manner at the site of action, enhancing therapeutic outcomes and minimizing systemic absorption.

In the area of HIV/AIDS treatment, CDDS are increasingly being used to provide long-acting formulations that reduce the frequency of dosing and improve patient adherence. Injectable formulations of antiretroviral drugs like cabotegravir are designed for bi-monthly or monthly administration, which is a significant improvement over daily oral regimens. These formulations provide sustained drug release, enhancing viral suppression and improving patient convenience (Owen & Kinch, 2020).

Gene therapy is an emerging field where CDDS are applied to deliver genetic material such as DNA or RNA to specific tissues.

Nanoparticles and liposomes are used to encapsulate genetic material and release it in a controlled manner, targeting the affected cells and tissues for therapeutic interventions. The success of mRNA vaccines, such as those developed for COVID-19, demonstrates the potential of CDDS in the realm of vaccine delivery, where the controlled release of antigens can improve immune responses and provide longer-lasting protection (Rojanasakul & Mukherjee, 2017).

Finally, CDDS play a pivotal role in the field of oral drug delivery. Extended-release tablets and capsules are designed to release the drug over a prolonged period, improving bioavailability and minimizing fluctuations in drug concentration. These formulations are particularly beneficial for drugs that require steady blood levels over time, such as analgesics and antihypertensives. The development of these systems has greatly enhanced the efficacy and convenience of oral drug administration (Wagner & Mehta, 2016).

The future of Controlled Drug Delivery Systems (CDDS) is highly promising, with numerous advancements poised to transform therapeutic approaches across various medical fields. One of the most notable prospects is the integration of personalized medicine, which will enable CDDS to be tailored based on individual genetic profiles, disease types, and patient responses to therapy. This will enhance the precision and effectiveness of treatments.

Additionally, the development of smart drug delivery systems that respond to specific internal or external stimuli, such as pH, temperature, or light, will allow for highly targeted and time-controlled drug release, especially in the treatment of diseases like cancer. Nanotechnology also offers immense potential, with the creation of nanoparticles and other nanomaterials that can carry drugs directly to target tissues, improving bioavailability and minimizing side effects. Moreover, biodegradable and biocompatible systems will continue to evolve, utilizing materials that degrade safely in the body, minimizing toxicity. Another exciting future direction is the development of long-acting, sustained-release formulations, which can enhance patient compliance by reducing the frequency of dosing.

The use of gene therapy and genome editing technologies, particularly CRISPR, in combination with CDDS, may lead to groundbreaking treatments for genetic disorders and other complex diseases. Furthermore, innovations such as 3D printing of drug delivery devices and micro/nanorobots for targeted drug delivery hold promise for the future of medicine, offering the possibility of even more precise and personalized therapies. However, these advancements will require addressing regulatory and ethical challenges to ensure safety and efficacy. Overall, the future of CDDS looks to revolutionize the landscape of medical treatments, improving outcomes and the quality of life for patients worldwide.

CONCLUSION

Controlled drug delivery systems (CDDS) are an essential tool in modern pharmacology, offering numerous advantages such as sustained drug release, reduced side effects, and improved patient compliance. The various types of CDDS, including oral, injectable, transdermal, and stimuli-responsive systems, have been developed to address the specific needs of different therapeutic areas. The

continuous evolution of materials, technologies, and mechanisms in drug delivery promises to enhance the efficacy and safety of drug therapies. The versatility of Controlled Drug Delivery Systems in various therapeutic areas highlights their significant contribution to modern medicine. By offering controlled, sustained, and targeted release of drugs, these systems improve therapeutic outcomes, reduce side effects, and enhance patient compliance. As technology continues to evolve, the potential applications of CDDS in the treatment of complex diseases, such as cancer, neurological disorders, and genetic diseases, will only expand, further revolutionizing drug delivery strategies.

DECLARATION OF INTEREST

The authors declare no conflicts of interests. The authors alone are responsible for the content and writing of this article.

REFERENCES

- Ahmad, M. & Akhter, N. (2017) Controlled drug delivery systems in the treatment of chronic diseases. *Journal of Controlled Release*, 264, 85–103.
- Allen, T.M. & Cullis, P.R. (2013) Liposomal drug delivery systems: From concept to clinical applications. *Advanced Drug Delivery Reviews*, 65, 36–48.
- Bhalekar, M.R. & Momin, M.A. (2015) Drug delivery systems: An overview. *International Journal of Research in Pharmacy and Pharmaceutical Sciences*, 1, 1–5.
- Binkowski, M. & Schofield, S. (2015) Controlled drug delivery systems for ocular applications. *Journal of Controlled Release*, 208, 51–60.
- Dash, S. & Konkimalla, V.B. (2012) Polymeric controlled drug delivery systems. *Journal of Pharmaceutical Sciences*, 101, 1012–1020.
- Dinarvand, R. & Mottaghitalab, V. (2013) Drug delivery systems: From fundamentals to advanced applications. *Pharmaceutical Research*, 30, 3648–3659.
- Jain, S. & Jain, A. (2009) Controlled and sustained release of drugs from polymeric formulations. *Journal of Drug Delivery Science and Technology*, 19, 251–257.
- Liu, J. & Zhang, Z. (2013) Stimuli-responsive drug delivery systems. *Journal of Controlled Release*, 167, 143–156.
- Melendez, J.E. & D'Costa, M. (2015) Controlled release in CNS drug delivery: Mechanisms and applications. *Pharmaceutical Research*, 32, 1–18.
- Owen, A. & Kinch, C. (2020) Long-acting formulations in HIV treatment. *Journal of Clinical Pharmacology*, 60, 473–485.
- Patel, H.M. & Patel, P. (2013) Liposomes and their applications in drug delivery. *Biomaterials*, 34, 2121–2130.
- Peppas, N.A. & Bures, P. (2004) Hydrogels in pharmaceutical formulations. *European Journal of Pharmaceutics and Biopharmaceutics*, 58, 179–188.

- Prausnitz, M.R. & Langer, R. (2008) Transdermal drug delivery. *Nature Biotechnology*, 26, 1261–1268.
- Ritschel, W.A. & Menges, K. (2009) Osmotic drug delivery systems: A critical review. *International Journal of Pharmaceutics*, 377, 18–26.
- Rojanasakul, Y. & Mukherjee, S. (2017) Nanotechnology applications in vaccine delivery. *Nanomedicine*, 13, 1–9.
- Shalviri, P. & Zeynizadeh, B. (2014) Controlled drug delivery from hydrogels: Applications and recent trends. *Asian Journal of Pharmaceutics*, 9, 72–79.
- Sharma, A. & Singh, B. (2015) Nanotechnology in drug delivery. *Current Pharmaceutical Design*, 21, 113–125.
- Siepmann, J. & Siepmann, F. (2012) Mathematical models in controlled drug delivery. *International Journal of Pharmaceutics*, 364, 301–314.
- Siepmann, J. & Siepmann, F. (2015) Polymer-based drug delivery systems. *European Journal of Pharmaceutics and Biopharmaceutics*, 93, 167–176.
- Wagner, J.G. & Mehta, S. (2016) The development and clinical applications of controlled drug delivery systems. *Pharmaceutical Development and Technology*, 21, 1–12.
- Zhang, L. & Wang, Y. (2014) Nanoparticles for drug delivery. *Advanced Drug Delivery Reviews*, 66, 48–56.
- Zhou, Q. & Ren, K. (2008) pH-sensitive controlled release systems for oral delivery of drugs. *Journal of Controlled Release*, 132, 150–155.
- Zhu, M. & Lin, J. (2015) Active transport drug delivery systems. *Journal of Controlled Release*, 211, 1–9.